EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT®
07 Mayo 2024 - 11:30AM
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION
TEST FOR BREAST CANCER ENDOPREDICT®
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO
ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER
ENDOPREDICT®
- Expansion in the oncology
segment
- Development of Eurobio
Scientific proprietary product portfolio
- Increase of international
exposure
Paris, 7th
May 2024 – 06:30 pm
Eurobio Scientific
(FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a
leading French group in in vitro specialty medical diagnostics and
life sciences, announces the signing on May 7th, 2024 of an
agreement to acquire all rights to second generation gene
expression test for breast cancer EndoPredict®
from Myriad Genetics. Consequently to this acquisition, Eurobio
Scientific will grant Myriad Genetics a license for the
manufacture, sale and distribution of the EndoPredict® Breast
Cancer Prognosis Test for laboratory developed tests (LDT) that is
mostly performed in the United States of America. In addition,
Myriad Genetics will grant Eurobio Scientific a license for the
manufacture, sale and distribution of Prolaris® Prostate Cancer
Prognostic Kit Test.
This acquisition and these agreements will allow
Eurobio Scientific to complete its oncology portfolio with
proprietary and distribution products. It will also strengthen its
geographical footprint, mainly in Europe. Completion of this
operation is expected in July 2024.
EndoPredict® is a highly
accurate second-generation multigene expression test for
early-stage breast cancer. It provides crucial information to guide
treatment decisions for patients with early-stage, hormone
receptor-positive (RE-positive) and HER2-negative breast cancer. It
predicts the risk of breast cancer recurrence (reappearance) up
to 15 years after the initial diagnosis, helping
clinicians determine whether a patient is at high or low risk for
recurrence.
About Myriad GeneticsMyriad
Genetics is a leading genetic testing and precision medicine
company dedicated to advancing health and well-being for all.
Myriad develops and offers genetic tests that help assess the risk
of developing disease or disease progression and guide treatment
decisions across medical specialties where genetic insights can
significantly improve patient care and lower healthcare costs. For
more information, visit www.myriad.com
| About
Eurobio ScientificEurobio Scientific is a key player in
the field of specialty in vitro diagnostics. It is involved from
research to manufacturing and commercialization of diagnostic tests
in the fields of transplantation, immunology and infectious
diseases, and sells instruments and products for research
laboratories, including biotechnology and pharmaceutical companies.
Through many partnerships and a strong presence in hospitals,
Eurobio Scientific has established its own distribution network and
a portfolio of proprietary products in the molecular biology field.
The Group has approximately 290 employees and four production units
based in the Paris region, in Germany, in the Netherlands and in
the United States, and several affiliates based in Dorking UK,
Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The
Netherlands and Milan in Italy.Eurobio Scientific's reference
shareholder is the EurobioNext holding company which brings
together its two directors, Jean-Michel Carle and Denis Fortier,
alongside the "Pépites et Territoires" by AXA & NextStage AM
investment program, managed by NextStage AM. For more information,
please visit: www.eurobio-scientific.comThe company is publicly
listed on the Euronext Growth market in ParisEuronext Growth BPI
Innovation, PEA-PME 150 and Next Biotech indices, Euronext European
Rising Tech label.Symbol: ALERS - ISIN Code: FR0013240934 -
Reuters: ALERS.PA - Bloomberg: ALERS:FP |
|
Contacts |
|
Groupe Eurobio ScientificDenis Fortier, Chairman
and CEO Olivier Bosc, Deputy CEO / CFO Tel. +33(0) 1 69 79 64
80 |
CalyptusMathieu CalleuxInvestors RelationsTel.
+33(1) 53 65 68 68 - eurobio-scientific@calyptus.net |
- 240705_EUROBIO_YELLOWSTONE_SPA_EN
Eurobio Scientific (EU:ALERS)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Eurobio Scientific (EU:ALERS)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
